Organic Acids
Medchemexpress LLC D2A21 TFA | >95.6% | 2775.42 | 1 MG
D2A21 TFA is an antimicrobial peptide that exhibits significant activity against Pseudomonas and has a bactericidal effect on burn scabs. This peptide also demonstrates antitumor activity, making it a candidate for research in prostate cancer.
- Antimicrobial peptide
- Active against Pseudomonas
- Bactericidal effect on burn scabs
- Antitumor activity
- Used in prostate cancer research
![Medchemexpress LLC L-Prolinamide, N,N-bis(phenylmethyl)glycyl]-4-[4-[[4-[[(phenylmethyl)amino]phosphonomethyl] | 99.87% | 1323.35 | 25 MG](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000384391-logo.png-250.jpg){kind=logo}
Medchemexpress LLC L-Prolinamide, N,N-bis(phenylmethyl)glycyl]-4-[4-[[4-[[(phenylmethyl)amino]phosphonomethyl] | 99.87% | 1323.35 | 25 MG
L-Prolinamide, N,N-bis(phenylmethyl)glycyl]-4-[4-[[4-[[(phenylmethyl)amino]phosphonomethyl] | 99.87% | 1323.35 | 25 MG
Medchemexpress LLC LP17 TFA (LQVTDSGLYRCVIYHPP TFA) | 99.2% | 1961.24 | 5 MG
LP17 (LQVTDSGLYRCVIYHPP) TFA is a BBB-penetrable triggering receptor expressed on myeloid cells (TREM-1) inhibitory peptide. It substantially alleviates ischemia-induced infarction and neuronal injury by accessing the brain and blocking TREM-1. For research use only.
- Decreases mRNA levels of pro-inflammatory cytokines and chemokines.
- Attenuates extracellular protein levels of IL-1β and IL-18 in a microglia oxygen-glucose deprivation (OGD) model.
- Interacts with microglial SYK.
- Alleviates ischemia-induced infarction and neuronal injury in mice.
- Reduces infarct volume by 27.3%.
- Reduces TUNEL positive cells and FJC positive neurons.
- Rescues neurological deficits and cognitive dysfunction.
- Inhibits microglial M1 polarization and neutrophil infiltration.
Medchemexpress LLC Vm24-toxin (Vaejovis mexicanus peptide 24) | 1373890-79-9 | 3863.59 | 1 MG
Vm24-toxin (Vaejovis mexicanus peptide 24) is a 36-residue peptide that acts as a potent and selective Kv1.3 blocker with a Kd of approximately 3 pM in lymphocytes. It exhibits over 1500-fold higher affinity for Kv1.3 compared to other assayed potassium channels. Vm24-toxin possesses a distorted cystine-stabilized α/β motif, comprising a single-turn α-helix and a three-stranded antiparallel β-sheet, stabilized by four disulfide bridges. This peptide can attenuate the CD4+ effector memory T cell response to T cell receptor (TCR) stimulation.
- Potent and selective Kv1.3 blocker
- High affinity for Kv1.3 over other potassium channels (>1500-fold)
- Attenuates CD4+ effector memory T cell response to T cell receptor (TCR) stimulation
Medchemexpress LLC Saralasin TFA | 34273-10-4 | 99.18% | 1026.07 | 25 MG
Saralasin TFA, an octapeptide analog of angiotensin II, functions as a competitive angiotensin II receptor antagonist and exhibits partial agonist activity. It is utilized in the research of renovascular hypertension and renin-dependent (angiotensinogenic) hypertension.
- Competitive angiotensin II receptor antagonist with a Ki value of 0.32 nM.
- Exhibits partial agonist activity.
- Inhibits cell growth in 3T3 and SV3T3 cells.
- Restores potassium currents in myocytes.
- Inhibits binding of FITC-Ang II to rat liver membrane preparation.
- Reduces ovulation rate and prostaglandin levels in vitro.
- Ameliorates oxidative stress and tissue injury in cerulein-induced pancreatitis in rats.
- Increases serum renin activity in normal, conscious rats.
Medchemexpress LLC LAGIPRA peptide (TFA) | 98.2% | 5756.50 (free base) | 5 MG
LAGIPRA peptide TFA is a long-acting GIP1R agonist that enhances insulin sensitivity by augmenting glucose disposal. It also reduces branched-chain amino acids (BCAAs) and ketoacids, making it a potential subject for research into type 2 diabetes.
- Long-acting GIP1R agonist
- Enhances insulin sensitivity by augmenting glucose disposal
- Reduces branched-chain amino acids (BCAAs) and ketoacids
- Potential for research into type 2 diabetes
Medchemexpress LLC CCZ01048 TFA | 98.5% | 1622.75 | 1 MG
CCZ01048 TFA is an α-MSH analogue that demonstrates high binding affinity to melanocortin 1 receptor (MC1R) with a Ki of 0.31 nM. It rapidly internalizes into B16F10 melanoma cells and exhibits high in vivo stability, making it a promising candidate for PET imaging of malignant melanoma. The cationic Pip linker used in CCZ01048 improves tumor uptake and generates high tumor-to-normal tissue contrast in PET imaging within a preclinical melanoma model.
- Exhibits high binding affinity to melanocortin 1 receptor (MC1R) with a Ki of 0.31 nM
- Rapid internalization into B16F10 melanoma cells
- Shows high in vivo stability
- Promising candidate for PET imaging of malignant melanoma
- Cationic Pip linker improves tumor uptake
- Generates high tumor-to-normal tissue contrast with PET imaging in a preclinical melanoma model
Medchemexpress LLC GIP, rat TFA | 99.8% | 5002.58 | 500 UG
GIP, rat TFA is a bioactive peptide of rat origin, also known as glucose-dependent insulinotropic polypeptide or gastric inhibitory polypeptide. This 42-amino acid peptide is released by K cells in the duodenum and jejunum in response to food intake. As a member of the insulinotropic hormone peptide family, it stimulates insulin secretion from pancreatic beta cells and appears to promote beta cell proliferation and survival. Recent studies suggest that GIP plays a role in lipid homeostasis and may be involved in the pathogenesis of obesity. It is for research use only.
- Bioactive peptide of rat origin
- 42-amino acid peptide
- Stimulates insulin secretion from pancreatic beta cells
- Promotes beta cell proliferation and survival
- Involved in lipid homeostasis and obesity pathogenesis (potential)
- For research use only
Medchemexpress LLC MS9427 TFA | 98.4% | 1107.50 | 5 MG
MS9427 TFA is a potent PROTAC EGFR degrader that selectively targets and degrades mutant EGFR through both the ubiquitin/proteasome system (UPS) and autophagy/lysosome pathways. This compound effectively inhibits the proliferation of NSCLC cells and shows antiproliferative activity against HCC-827 cells.
- Potent PROTAC EGFR degrader
- Selectively degrades mutant EGFR
- Utilizes ubiquitin/proteoteasome system and autophagy/lysosome pathways
- Inhibits proliferation of non-small cell lung cancer (NSCLC) cells
- Exhibits antiproliferative activity against HCC-827 cells
- Induces EGFRDel19 degradation
Medchemexpress LLC WP9QY (TFA) | 199999-60-5 | 98.7% | 1340.40 | 25 MG
WP9QY TFA is a biologically active cyclic peptide, serving as a TNF-α Antagonist. It is designed to mimic the critical tumor necrosis factor (TNF) recognition loop on TNF receptor I, preventing interactions of TNF with its receptor. This peptide is a useful template for developing small molecular inhibitors to prevent inflammatory bone destruction and systemic bone loss in rheumatoid arthritis. It is for research use only.
- Biologically active peptide
- TNF-α antagonist
- Mimics critical tumor necrosis factor recognition loop on TNF receptor I
- Prevents TNF interactions with its receptor
- Useful template for small molecular inhibitor development
- Prevents inflammatory bone destruction
- Prevents systemic bone loss in rheumatoid arthritis
- For research use only
Medchemexpress LLC Cef20 TFA | 99.3% | 1057.19 | 5 MG
CEF20 TFA is an HLA-A*0201-restricted epitope from cytomegalovirus pp65 (495-503). It is for research use only.
- An HLA-A*0201-restricted epitope from cytomegalovirus pp65 (495-503)
- For research use only
Medchemexpress LLC Vh4127 TFA | 1034.35 (free base) | 1 MG
VH4127 TFA is a cyclic peptide that targets the low-density lipoprotein receptor (LDLR) with a KD of 18 nM for hLDLR. It specifically binds to the epidermal growth factor (EGF) homology domain of both rodent and human LDLR.
- Targets low density lipoprotein receptor (LDLR)
- Has a high binding affinity (KD of 18 nM) for human LDLR
- Binds specifically to the EGF homology domain of rodent and human LDLR
- Available in various quantities
- For research use only
- Information on solubility, in vivo dissolution, and related antibodies is also available
Medchemexpress LLC GRGDSP TFA | 98.0% | 701.61 | 25 MG
GRGDSP (TFA) is an integrin inhibitor. This synthetic linear RGD peptide can inhibit the adherence of tumor cells to endothelial cells of blood vessels, thereby limiting metastasis. It is also utilized to modify the surface of cardiovascular implants, such as vascular grafts, to promote endothelialization, and is widely employed in integrin research as a soluble integrin-blocking RGD-based peptide.
- Inhibits adherence of tumor cells to endothelial cells of blood vessels
- Limits metastasis
- Promotes endothelialization for cardiovascular implants
- Used in integrin research
- Functions as a soluble integrin-blocking RGD-based peptide
Medchemexpress LLC TAT peptide TFA | 99.8% | 1735.93 | 25 MG
TAT peptide (TFA) is a cell penetrating peptide (GRKKRRQRRRPQ) derived from the trans-activating transcriptional activator (Tat) from HIV-1. It has been studied in functionalized hybrid nanoparticles for magnetic enrichment and optical detection in cell separation and rapid cell labelling, demonstrating good biocompatibility.
- Derived from trans-activating transcriptional activator (Tat) from HIV-1
- Cell penetrating peptide (GRKKRRQRRRPQ)
- Used in functionalized hybrid nanoparticles for cell separation
- Used in rapid cell labelling
- Shows good biocompatibility
- For research use only
Medchemexpress LLC Galnon (TFA) | 1217448-19-5 | MFCD06798339 | 98.9% | 792.84 g·mol⁻¹ | C42H47F3N4O8 | 25 MG
Galnon TFA is a selective, non-peptide agonist of the galanin receptors GAL1 and GAL2, with reported Ki values of 11.7 μM (GAL1) and 34.1 μM (GAL2). It is used in in vitro and in vivo research to study galanin receptor pharmacology and has demonstrated anticonvulsant and anxiolytic effects.
- Selective galanin receptor agonist with reported Ki values (GAL1 = 11.7 μM, GAL2 = 34.1 μM).
- Non-peptide small-molecule ligand suitable for receptor pharmacology studies.
- Demonstrated anticonvulsant and anxiolytic activity in preclinical studies.
- Supplied at high purity (98.88%) for research use.
- Available in small research-scale quantities, including 25 mg.